If you’re tired of losing sleep because you can’t take your eye off of the baby monitor, some much needed rest is on the way. AT&T and Exmovere have announced an agreement to wirelessly enable Exmovere’s patented biosensor baby pyjamas, Exmobaby.
Exmobaby is a snap-on transmitter designed to measure critical vital signs in infants, including heart rate, skin temperature, moisture and movement. The data is transmitted at regular intervals to the parent’s computer, tablet and smartphone and is used to interpret the baby’s emotional states and behaviour, transmitting alerts to parents and caregivers when their babies require attention or care.
The wireless transmitter device will be sold with pyjama garments available in four sizes ranging from 0 – 12 months. The transmitter device can easily be removed for washing.
With Exmobaby, parents, grandparents and caregivers will be conveniently equipped to monitor an infant when the pyjamas with the transmitter are worn. The biosensor capability provides parents with continuous information about their baby and enables baby monitoring.
A significant concern for all parents, and especially new parents, is the risk of Sudden Infant Death Syndrome (SIDS). The medical community has yet to identify the causes of SIDS, but there are significant efforts underway in most parts of the world to educate new parents on many of the preventative measures that can be undertaken to ease their fears and help keep their babies safe. By sending data across the AT&T wireless network, Exmobaby provides tracking and reporting of what babies are actually feeling, in real-time.
“Providing parents and caregivers access to real-time baby monitoring and special alerts through a wirelessly connected device should help deliver unprecedented peace of mind,” said Glenn Lurie, president, emerging devices, AT&T. “It meets the needs of today’s parents and caregivers who want to stay connected to their children, their well being, and what’s happening around them, especially when it comes to newborns.”
Exmobaby is not designed for medical diagnosis or treatment, nor does the software create any information related to treatment regimens. Exmovere intends to submit pre-market notice to the FDA before releasing Exmobaby to consumers. As a monitor, Exmobaby’s ability to take advantage of biosensor and wireless communication technologies are ahead of traditional, “walkie talkie”-style baby monitors.
